Non 24 Hour Sleep Wake Disorder clinical trials

Explore recruiting non 24 hour sleep wake disorder clinical trials.

Also recruiting in Europe

Non 24 Hour Sleep Wake Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

OPEN-LABEL SAFETY STUDY OF A 1-YEAR 20MG DOSE REGIMEN OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER (N24HSWD) IN BLIND INDIVIDUALS WITH NO LIGHT PERCEPTION

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non 24 Hour Sleep Wake Disorder trials by city

Non 24 Hour Sleep Wake Disorder in Toronto Non 24 Hour Sleep Wake Disorder in Vancouver Non 24 Hour Sleep Wake Disorder in Montreal Non 24 Hour Sleep Wake Disorder in Calgary Non 24 Hour Sleep Wake Disorder in Edmonton Non 24 Hour Sleep Wake Disorder in Ottawa Non 24 Hour Sleep Wake Disorder in Winnipeg Non 24 Hour Sleep Wake Disorder in Quebec City Non 24 Hour Sleep Wake Disorder in Hamilton Non 24 Hour Sleep Wake Disorder in Kitchener Non 24 Hour Sleep Wake Disorder in London Non 24 Hour Sleep Wake Disorder in Halifax Non 24 Hour Sleep Wake Disorder in New York Non 24 Hour Sleep Wake Disorder in Los Angeles Non 24 Hour Sleep Wake Disorder in Chicago Non 24 Hour Sleep Wake Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease